ES2345673T3 - Eritropoyetina en dosis subpolicitemicas para el tratamiento de la diabetes. - Google Patents
Eritropoyetina en dosis subpolicitemicas para el tratamiento de la diabetes. Download PDFInfo
- Publication number
- ES2345673T3 ES2345673T3 ES07001689T ES07001689T ES2345673T3 ES 2345673 T3 ES2345673 T3 ES 2345673T3 ES 07001689 T ES07001689 T ES 07001689T ES 07001689 T ES07001689 T ES 07001689T ES 2345673 T3 ES2345673 T3 ES 2345673T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- epo
- use according
- endothelial
- erythropoietin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 18
- 230000003511 endothelial effect Effects 0.000 claims abstract description 94
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 44
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 11
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 8
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims abstract description 7
- 102100035194 Placenta growth factor Human genes 0.000 claims abstract description 7
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims abstract 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 116
- 102000003951 Erythropoietin Human genes 0.000 claims description 114
- 108090000394 Erythropoietin Proteins 0.000 claims description 114
- 229940105423 erythropoietin Drugs 0.000 claims description 112
- 210000000130 stem cell Anatomy 0.000 claims description 80
- 239000013543 active substance Substances 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 15
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 9
- 230000000638 stimulation Effects 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 4
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 4
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 4
- 229960005370 atorvastatin Drugs 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229960002855 simvastatin Drugs 0.000 claims description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 4
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 3
- 229950009116 mevastatin Drugs 0.000 claims description 3
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 102100029108 Elongation factor 1-alpha 2 Human genes 0.000 claims 1
- 101000841231 Homo sapiens Elongation factor 1-alpha 2 Proteins 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 53
- 210000002889 endothelial cell Anatomy 0.000 abstract description 19
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- 230000004069 differentiation Effects 0.000 abstract description 12
- 230000035755 proliferation Effects 0.000 abstract description 12
- 230000002491 angiogenic effect Effects 0.000 abstract description 10
- 230000005012 migration Effects 0.000 abstract description 10
- 238000013508 migration Methods 0.000 abstract description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract description 9
- 210000004204 blood vessel Anatomy 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 8
- 230000004862 vasculogenesis Effects 0.000 abstract description 8
- 210000000056 organ Anatomy 0.000 abstract description 7
- 230000000982 vasogenic effect Effects 0.000 abstract description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000004936 stimulating effect Effects 0.000 abstract description 5
- 230000002792 vascular Effects 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- WGUYYUOFQYVTLR-BLPRJPCASA-N [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO Chemical compound [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO WGUYYUOFQYVTLR-BLPRJPCASA-N 0.000 abstract 1
- 230000003257 anti-anginal effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002402 anti-lipaemic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 210000003709 heart valve Anatomy 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 208000020832 chronic kidney disease Diseases 0.000 description 26
- 201000010099 disease Diseases 0.000 description 25
- 108010019673 Darbepoetin alfa Proteins 0.000 description 24
- 229940115115 aranesp Drugs 0.000 description 24
- 230000004064 dysfunction Effects 0.000 description 21
- 235000002639 sodium chloride Nutrition 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 15
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 15
- 230000006698 induction Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 210000001367 artery Anatomy 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 210000003038 endothelium Anatomy 0.000 description 9
- 230000036732 histological change Effects 0.000 description 9
- 201000006370 kidney failure Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 241000700157 Rattus norvegicus Species 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- 210000001956 EPC Anatomy 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 210000003041 ligament Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 4
- 108050009340 Endothelin Proteins 0.000 description 4
- 102000002045 Endothelin Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 4
- 102000044890 human EPO Human genes 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 229940069575 rompun Drugs 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 4
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000013059 nephrectomy Methods 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 102100022987 Angiogenin Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020852 Hypertonia Diseases 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 2
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 206010038470 Renal infarct Diseases 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000000648 angioblast Anatomy 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000006442 vascular tone Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 101710105077 Agglutinin-1 Proteins 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000013925 CD34 antigen Human genes 0.000 description 1
- 108050003733 CD34 antigen Proteins 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000002087 Endarteritis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000219871 Ulex Species 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000017570 negative regulation of blood coagulation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009543 pathological alteration Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000020971 positive regulation of blood coagulation Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10234192 | 2002-07-26 | ||
| DE10234192A DE10234192B4 (de) | 2002-07-26 | 2002-07-26 | Verwendung von Erythropoetin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2345673T3 true ES2345673T3 (es) | 2010-09-29 |
Family
ID=30128436
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03766302T Expired - Lifetime ES2285195T3 (es) | 2002-07-26 | 2003-07-25 | Eritropoyetina en dosis subpolicitemicas. |
| ES07001689T Expired - Lifetime ES2345673T3 (es) | 2002-07-26 | 2003-07-25 | Eritropoyetina en dosis subpolicitemicas para el tratamiento de la diabetes. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03766302T Expired - Lifetime ES2285195T3 (es) | 2002-07-26 | 2003-07-25 | Eritropoyetina en dosis subpolicitemicas. |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7745387B2 (OSRAM) |
| EP (3) | EP1526867B1 (OSRAM) |
| JP (4) | JP4727988B2 (OSRAM) |
| KR (2) | KR20100077033A (OSRAM) |
| CN (3) | CN101099731B (OSRAM) |
| AT (2) | ATE360436T1 (OSRAM) |
| AU (2) | AU2003255290B2 (OSRAM) |
| BR (1) | BR0312981A (OSRAM) |
| CA (2) | CA2493598A1 (OSRAM) |
| CY (2) | CY1108052T1 (OSRAM) |
| DE (3) | DE10234192B4 (OSRAM) |
| DK (2) | DK1779862T3 (OSRAM) |
| EA (3) | EA013966B1 (OSRAM) |
| ES (2) | ES2285195T3 (OSRAM) |
| HR (3) | HRP20100187A2 (OSRAM) |
| IL (2) | IL166401A0 (OSRAM) |
| IS (3) | IS2671B (OSRAM) |
| MX (1) | MXPA05001120A (OSRAM) |
| NO (1) | NO20051002L (OSRAM) |
| PL (2) | PL374874A1 (OSRAM) |
| PT (2) | PT1526867E (OSRAM) |
| SG (1) | SG177004A1 (OSRAM) |
| SI (2) | SI1526867T1 (OSRAM) |
| UA (2) | UA85997C2 (OSRAM) |
| WO (1) | WO2004012759A2 (OSRAM) |
| ZA (1) | ZA200500726B (OSRAM) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| ES2369487T3 (es) * | 2003-07-29 | 2011-12-01 | Dompe' S.P.A. | Combinación farmacéutica de g-csf y plgf útil para células madre de sangre. |
| WO2005063965A1 (de) * | 2003-12-30 | 2005-07-14 | Bionethos Holding Gmbh | Verfahren zur regeneration von gewebe |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
| JP2008522980A (ja) | 2004-12-06 | 2008-07-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 小血管の構造および機能を改善するための方法 |
| AR053416A1 (es) | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EA201692543A1 (ru) | 2005-11-23 | 2017-08-31 | Акселерон Фарма Инк. | Антагонисты активина-actriia и их применение для стимулирования роста кости |
| JP5326079B2 (ja) * | 2006-06-07 | 2013-10-30 | 国立大学法人徳島大学 | エリスロポエチンを用いた虚血性疾患の治療 |
| BRPI0717155A2 (pt) * | 2006-09-29 | 2013-10-15 | Centocor Ortho Biotech Inc | Agonistas do receptor de epo humana, composições, métodos e usos para prevenção ou tratamento das condições relacionadas á intolerância á glicose |
| CA2666809A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Anti-cancer agent comprising anti-hb-egf antibody as active ingredient |
| EP3040347A3 (en) * | 2006-10-20 | 2016-09-21 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| US8975374B2 (en) * | 2006-10-20 | 2015-03-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2674368A1 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| TWI432449B (zh) | 2007-02-02 | 2014-04-01 | Acceleron Pharma Inc | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| AR065613A1 (es) * | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
| US20110123481A1 (en) * | 2007-08-16 | 2011-05-26 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications |
| EP2303309A2 (en) * | 2008-05-22 | 2011-04-06 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| PT2340031T (pt) | 2008-08-14 | 2019-07-25 | Acceleron Pharma Inc | Armadilhas de gdf para uso no tratamento de anemia |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| RU2642302C1 (ru) * | 2009-08-13 | 2018-01-24 | Акселерон Фарма Инк. | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов |
| WO2011063018A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| EP2590666B1 (en) | 2010-07-06 | 2017-04-26 | Augustinus Bader | Topical application of erythropoietin for use in the treatment of injuries of the cornea |
| US9956265B2 (en) | 2011-04-26 | 2018-05-01 | Ajou University Industry-Academic Cooperation Foundation | Composition for aiding surgical procedures for treating ischemic vascular diseases |
| WO2015061431A1 (en) * | 2013-10-22 | 2015-04-30 | ConcieValve LLC | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
| BR112016029226A2 (pt) | 2014-06-13 | 2017-10-17 | Acceleron Pharma Inc | métodos e composições para o tratamento de úlceras |
| US11241505B2 (en) * | 2015-02-13 | 2022-02-08 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN105233256A (zh) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用 |
| US11534466B2 (en) * | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| GB2550114A (en) * | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
| US10576167B2 (en) | 2016-08-17 | 2020-03-03 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN108114282B (zh) * | 2016-11-28 | 2021-03-02 | 北京大学第三医院 | 他汀类化合物治疗缺血性疾病的用途 |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| WO2019078344A1 (ja) * | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| RU2695334C1 (ru) * | 2018-09-25 | 2019-07-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте |
| RU2678768C1 (ru) * | 2018-09-25 | 2019-02-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте |
| KR20220039719A (ko) | 2019-07-03 | 2022-03-29 | 팩터 바이오사이언스 인크. | 양이온성 지질 및 이의 용도 |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| CN119080909A (zh) * | 2024-08-29 | 2024-12-06 | 深圳赛保尔生物药业有限公司 | 负载peg-epo及间充质干细胞的组合物、药物及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4732889A (en) | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
| US5198417A (en) * | 1985-11-27 | 1993-03-30 | Genetics Institute, Inc. | Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors |
| EP0246322B1 (en) | 1985-11-27 | 1992-08-26 | Genetics Institute, Inc. | Treatment of aids-type disease |
| DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US5013718A (en) | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| DE3729863A1 (de) | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| EP0424386A1 (en) * | 1988-02-24 | 1991-05-02 | American National Red Cross | Device for site directed neovascularization and method for same |
| US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| DE4014654A1 (de) | 1990-05-08 | 1991-11-14 | Behringwerke Ag | Galenische waessrige formulierungen von erythropoietin und ihre verwendung |
| JP3627985B2 (ja) * | 1991-03-11 | 2005-03-09 | キュリス インコーポレイテッド | タンパク質により誘導される形態形成 |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| AU697453B2 (en) | 1993-04-29 | 1998-10-08 | Abbott Laboratories | Erythropoietin analog compositions and methods |
| IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
| JPH08205860A (ja) * | 1994-01-21 | 1996-08-13 | Usa Government | 造血細胞の膨大化および移植方法 |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| ES2206521T3 (es) | 1994-11-03 | 2004-05-16 | Roche Diagnostics Gmbh | Utilizacion de la eritropoyetina en el tratamiento de artritis reumatoide. |
| US5837675A (en) | 1995-02-03 | 1998-11-17 | Brox; Alan G. | Synergistic effect of insulin-like growth factor-I and erythropoietin |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| US6274158B1 (en) * | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
| US6284260B1 (en) | 1998-02-04 | 2001-09-04 | Veronica L. Zaharia Czeizler | Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| NZ514690A (en) * | 1999-04-13 | 2004-07-30 | Kenneth S | Modulation of excitable tissue function by peripherally administered erythropoietin |
| AU5462601A (en) | 2000-05-02 | 2001-11-12 | Action Pharmaceuticals Aps | Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| US7259146B2 (en) * | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US20020065214A1 (en) * | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
| PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| AU2002319142B2 (en) * | 2001-04-04 | 2008-02-21 | Genodyssee | New polynucleotides and polypeptides of the erythropoietin gene |
| US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| NZ532988A (en) * | 2001-11-28 | 2008-04-30 | Ortho Mcneil Pharm Inc | Erythropoietin dosing regimen for treating anemia |
| ATE359087T1 (de) * | 2002-01-09 | 2007-05-15 | Crucell Holland Bv | Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen |
| US6748154B2 (en) * | 2002-03-28 | 2004-06-08 | Nortel Networks Limited | Optical module access tray |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
-
2002
- 2002-07-26 DE DE10234192A patent/DE10234192B4/de not_active Expired - Fee Related
-
2003
- 2003-07-25 PL PL03374874A patent/PL374874A1/xx unknown
- 2003-07-25 CA CA002493598A patent/CA2493598A1/en not_active Abandoned
- 2003-07-25 ES ES03766302T patent/ES2285195T3/es not_active Expired - Lifetime
- 2003-07-25 EA EA200700196A patent/EA013966B1/ru not_active IP Right Cessation
- 2003-07-25 SI SI200330881T patent/SI1526867T1/sl unknown
- 2003-07-25 KR KR1020107011097A patent/KR20100077033A/ko not_active Ceased
- 2003-07-25 JP JP2004525322A patent/JP4727988B2/ja not_active Expired - Fee Related
- 2003-07-25 HR HR20100187A patent/HRP20100187A2/xx not_active Application Discontinuation
- 2003-07-25 DK DK07001689.4T patent/DK1779862T3/da active
- 2003-07-25 AT AT03766302T patent/ATE360436T1/de not_active IP Right Cessation
- 2003-07-25 EP EP03766302A patent/EP1526867B1/de not_active Expired - Lifetime
- 2003-07-25 HR HR20050065A patent/HRP20050065A2/hr not_active Application Discontinuation
- 2003-07-25 ES ES07001689T patent/ES2345673T3/es not_active Expired - Lifetime
- 2003-07-25 BR BR0312981-0A patent/BR0312981A/pt not_active IP Right Cessation
- 2003-07-25 CN CN200710127913XA patent/CN101099731B/zh not_active Expired - Fee Related
- 2003-07-25 MX MXPA05001120A patent/MXPA05001120A/es active IP Right Grant
- 2003-07-25 CN CNA038221160A patent/CN1681526A/zh active Pending
- 2003-07-25 CA CA2710100A patent/CA2710100A1/en not_active Abandoned
- 2003-07-25 EP EP10000381A patent/EP2191838A1/de not_active Withdrawn
- 2003-07-25 KR KR1020057001341A patent/KR20050026513A/ko not_active Ceased
- 2003-07-25 DE DE50312729T patent/DE50312729D1/de not_active Expired - Lifetime
- 2003-07-25 PT PT03766302T patent/PT1526867E/pt unknown
- 2003-07-25 PT PT07001689T patent/PT1779862E/pt unknown
- 2003-07-25 SI SI200331837T patent/SI1779862T1/sl unknown
- 2003-07-25 EP EP07001689A patent/EP1779862B1/de not_active Expired - Lifetime
- 2003-07-25 US US10/522,426 patent/US7745387B2/en not_active Expired - Fee Related
- 2003-07-25 EA EA200801236A patent/EA200801236A1/ru unknown
- 2003-07-25 AT AT07001689T patent/ATE468132T1/de not_active IP Right Cessation
- 2003-07-25 SG SG2007003890A patent/SG177004A1/en unknown
- 2003-07-25 EA EA200500281A patent/EA009463B1/ru not_active IP Right Cessation
- 2003-07-25 PL PL395151A patent/PL395151A1/pl unknown
- 2003-07-25 HR HR20070189A patent/HRP20070189A2/xx not_active Application Discontinuation
- 2003-07-25 AU AU2003255290A patent/AU2003255290B2/en not_active Ceased
- 2003-07-25 DE DE50307140T patent/DE50307140D1/de not_active Expired - Lifetime
- 2003-07-25 UA UAA200501760A patent/UA85997C2/ru unknown
- 2003-07-25 CN CN2007101279144A patent/CN101099860B/zh not_active Expired - Fee Related
- 2003-07-25 WO PCT/EP2003/008229 patent/WO2004012759A2/de not_active Ceased
- 2003-07-25 UA UAA200801307A patent/UA94913C2/ru unknown
- 2003-07-25 DK DK03766302T patent/DK1526867T3/da active
-
2005
- 2005-01-06 IS IS7633A patent/IS2671B/is unknown
- 2005-01-20 IL IL16640105A patent/IL166401A0/xx not_active IP Right Cessation
- 2005-01-25 ZA ZA200500726A patent/ZA200500726B/xx unknown
- 2005-02-24 NO NO20051002A patent/NO20051002L/no not_active Application Discontinuation
-
2007
- 2007-07-02 CY CY20071100871T patent/CY1108052T1/el unknown
-
2009
- 2009-02-25 AU AU2009200748A patent/AU2009200748A1/en not_active Abandoned
- 2009-05-06 IS IS8817A patent/IS8817A/is unknown
-
2010
- 2010-03-18 IL IL204577A patent/IL204577A/en not_active IP Right Cessation
- 2010-04-13 US US12/759,275 patent/US20100247450A1/en not_active Abandoned
- 2010-04-13 US US12/759,321 patent/US20100247452A1/en not_active Abandoned
- 2010-04-13 US US12/759,299 patent/US20100247451A1/en not_active Abandoned
- 2010-07-02 IS IS8909A patent/IS8909A/is unknown
- 2010-07-09 JP JP2010157093A patent/JP2010280671A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157094A patent/JP2010280672A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157092A patent/JP2010280670A/ja not_active Withdrawn
- 2010-07-29 CY CY20101100712T patent/CY1110713T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2345673T3 (es) | Eritropoyetina en dosis subpolicitemicas para el tratamiento de la diabetes. | |
| AU2010200621A1 (en) | Use of low-dose erythropoietin for stimulation of endothelial progenitor cells, for organ regeneration and for slowing the progression of end-organ damage | |
| KR20210123838A (ko) | 탈모의 예방 또는 치료용 펩티드 및 이의 이용 | |
| JP2003192541A (ja) | 育毛促進剤及び育毛用の皮膚外用剤 | |
| NZ537860A (en) | Use of erythropoietin for the treatment of chronic renal failure | |
| WO2005097170A1 (ja) | 血管新生促進剤および血管新生療法 | |
| HK1108625B (en) | Erythropoietin in subpolycythemic doses for treating diabetes |